ClinicalTrials.gg
CompletedNCT01836458Updated Oct 31, 2016Results posted

A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection

A Phase 2 interventional study of KAE609 in Malaria, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Vietnam. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2016-10-31.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Malaria by Novartis — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Novartis.

Enrollment
16th of 21
25 · median 57
Started
2014
with 1 other
Phase 2
6 of 24
1 open now
Registered
11th of 24
by date

Among the 24 studies in Malaria by Novartis, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 2, and was the 11th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 24 studies in Malaria by Novartis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Malaria by Novartis, or all of them as a file.
02

Study summary

This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single dosing with KAE609

Read the detailed description

There will be a total of approximately 45 patients recruited into this study and six doses of KAE609 and will be investigated.The dose groups will run in sequence. Patient will be given a single dose of KAE609 and be followed up for 42 days.

03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • Malaria, KAE609
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Monoinfection with P. falciparum confirmed by microscopy
  • Asexual P. falciparum parasitemia count of 5,000 to 50,000/µL
  • Axillary temperature ≥37.5 ºC or oral/tympanic/rectal temperature ≥38 ºC; or similar documented temperature during the previous 24 hours
  • Body weight between 40 to 90 kg

Key Exclusion Criteria:

  • Signs and symptoms of severe malaria according to World Health Organization (WHO) 2010 criteria
  • Mixed Plasmodium infection, i.e. infection with more than one species of malaria parasites
  • Use of other drugs within 30 days or within 5 half-lives of enrollment, whichever is longer
  • History of antimalarial use within 2 months of screening
  • Use of any antibiotics with antimalarial activity or other prohibited medication within 14 days of screening
  • Long syndrome or QTc using Fridericia's formula >430 msec
  • History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or
  • level \<10 g/dL
  • Liver disease or injury as indicated by elevated liver tests such as (ALT) or SGOT (AST) >2 times the
  • Renal dysfunction as indicated by serum creatinine >2 times the upper limit of normal in the absence of dehydration; in case of dehydration, serum creatinine should be \<2 times the upper limit of normal after oral or parental rehydration
  • Known to be (including infection) or are receiving immunosuppressive therapy at the time or enrollment; HIV testing is not required
  • Known history of or C; testing is not required
  • Febrile condition due to diseases other than malaria (e.g. acute lower respiratory tract infection), known underlying chronic or severe disease (e.g. cardiac, hepatic, renal, gastrointestinal, neurologic, or psychiatric disease), or any condition precluding enrollment into this study according to the investigator
  • Severe vomiting defined as >3 times during the previous 24 hours or inability to tolerate oral medication; severe diarrhea defined as ≥3 watery stools during the previous 24 hours
  • Severe malnutrition defined by a (BMI) \<18.5 kg/m2 or unintentional loss of weight ≥10% with evidence of suboptimal intake resulting in loss of subcutaneous fat and/or severe muscle wasting
  • Active tuberculosis or history of taking anti-tuberculosis medications within 24 months prior to screening
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Dose 1: 30 mg

    Single dose of KAE609 30 mg

    Drug: KAE609

  • Experimental
    Dose 2: 20 mg

    Single dose of KAE609 20 mg

    Drug: KAE609

  • Experimental
    Dose 3: 10 mg

    Single dose of KAE609 10 mg

    Drug: KAE609

  • Experimental
    Dose 4: 15 mg

    Single dose of KAE609 15 mg

    Drug: KAE609

Interventions

  • DrugKAE609

    Patients will receive KAE609 single dose at a different dose level in each cohort.

06

What researchers measure

Primary outcomes

  1. Minimum Inhibitory Concentration (MIC) of KAE609

    To observe the exposure-response (PK/PD) relationship for a single dose of KAE609. The key parameter is MIC, defined as the concentration at which the relative rate of change in parasitemia is equal to zero. Approximation of MIC will assist in identifying the optimal dose of KAE609, which will be one component of a future combination antimalarial. MIC could not be determined due to small sample size no data was collected from any participants.

    Time frame: Up to Day 8 after a single dose of KAE609

Secondary outcomes

  1. Median Time to Parasite Clearance

    Parasite clearance time will be estimated using thick/thin blood films.

    Time frame: pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 54, 60, 66, 72 hours post dose of KAE609

  2. Median Time to Fever Clearance

    Fever is monitored on participants every 4 hours for the first 24 hours, then every 6 hours until negative reading obtained.

    Time frame: Day 1 to Day 5

  3. Percentage of Patients PCR-corrected Cure Rate by Day 28, Day 35 & Day 42

    PCR-corrected cure rate after a single dose of KAE609 by Day 28, Day 35 \& Day 42. PCR-corrected cure rate accounts for failures due to reappearance of parasites that were present in the blood before treatment (i.e. recrudescent infection) but not for failures due to a post-treatment inoculation (i.e. new infection).

    Time frame: Day 28, Day 35 & Day 42

07

Results

Posted Oct 31, 2016

Participant flow

Participant flow — Overall Study
MilestoneDose 1: 30 mgDose 2: 20 mgDose 3: 10 mgDose 4: 15 mg
Started7477
Completed4221
Not completed3256
Withdrew: Unsatisfactory therapeutic effect3256

Outcome measures

PrimaryMinimum Inhibitory Concentration (MIC) of KAE609

To observe the exposure-response (PK/PD) relationship for a single dose of KAE609. The key parameter is MIC, defined as the concentration at which the relative rate of change in parasitemia is equal to zero. Approximation of MIC will assist in identifying the optimal dose of KAE609, which will be one component of a future combination antimalarial. MIC could not be determined due to small sample size no data was collected from any participants.

Time frame:
Up to Day 8 after a single dose of KAE609

No measurements were reported for this outcome.

SecondaryMedian Time to Parasite Clearance

Parasite clearance time will be estimated using thick/thin blood films.

Time frame:
pre-dose, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, 48, 54, 60, 66, 72 hours post dose of KAE609
Reported as:
Median · hours
Median Time to Parasite Clearance
hoursDose 1: 30 mgDose 2: 20 mgDose 3: 10 mgDose 4: 15 mg
Median Time to Parasite Clearance24.00 (12.00 to 48.00)63.00 (36.02 to 72.00)54.00 (36.05 to NA)60.00 (36.00 to 72.00)
SecondaryMedian Time to Fever Clearance

Fever is monitored on participants every 4 hours for the first 24 hours, then every 6 hours until negative reading obtained.

Time frame:
Day 1 to Day 5
Reported as:
Median · hours
Median Time to Fever Clearance
hoursDose 1: 30 mgDose 2: 20 mgDose 3: 10 mgDose 4: 15 mg
Median Time to Fever Clearance9.83 (0.83 to 11.92)12.38 (3.83 to 29.83)15.75 (0.75 to 15.83)11.83 (4.83 to 35.83)
SecondaryPercentage of Patients PCR-corrected Cure Rate by Day 28, Day 35 & Day 42

PCR-corrected cure rate after a single dose of KAE609 by Day 28, Day 35 \& Day 42. PCR-corrected cure rate accounts for failures due to reappearance of parasites that were present in the blood before treatment (i.e. recrudescent infection) but not for failures due to a post-treatment inoculation (i.e. new infection).

Time frame:
Day 28, Day 35 & Day 42
Reported as:
Number · Percentage of Patients
Percentage of Patients PCR-corrected Cure Rate by Day 28, Day 35 & Day 42
Percentage of PatientsDose 1: 30 mgDose 2: 20 mgDose 3: 10 mgDose 4: 15 mg
Day 2857.150.028.614.3
Day 3557.150.028.614.3
Day 4257.150.028.614.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose 1: 30mg—0/7 (0%)4/7 (57.1%)
Dose 2: 20mg—0/4 (0%)3/4 (75%)
Dose 3: 10mg—0/7 (0%)7/7 (100%)
Dose 4: 15mg—0/7 (0%)5/7 (71.4%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventDose 1: 30mgDose 2: 20mgDose 3: 10mgDose 4: 15mg
Blood alkaline phosphatase increasedInvestigations1/72/43/74/7
HyperbilirubinaemiaHepatobiliary disorders0/71/43/71/7
Abnormal faecesGastrointestinal disorders0/71/40/70/7
HeadacheNervous system disorders1/71/40/70/7
CoughRespiratory, thoracic and mediastinal disorders0/71/40/70/7
AnaemiaBlood and lymphatic system disorders0/70/41/70/7
Abdominal pain upperGastrointestinal disorders0/70/41/70/7
DiarrhoeaGastrointestinal disorders0/70/40/71/7
NauseaGastrointestinal disorders1/70/41/70/7
Alanine aminotransferase increasedInvestigations1/70/40/70/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dose 1: 30 mgDose 2: 20 mgDose 3: 10 mgDose 4: 15 mgTotal
Mean32.7 ± 11.8432.8 ± 7.9330.6 ± 8.2434.7 ± 8.7932.7 ± 9.04
Sex/Gender, Customized
Sex/Gender, Customized(participants)Dose 1: 30 mgDose 2: 20 mgDose 3: 10 mgDose 4: 15 mgTotal
MALE747725
08

Study locations

1 site
  • Novartis Investigative Site
    Ho Chi Minh, Vietnam
09

References and documents

Publications

  • Hien TT, White NJ, Thuy-Nhien NT, Hoa NT, Thuan PD, Tarning J, Nosten F, Magnusson B, Jain JP, Hamed K. Estimation of the In Vivo MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01940-16. doi: 10.1128/AAC.01940-16. Print 2017 Feb. PubMed 27872070 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2013
First posted
Apr 19, 2013
Start
Jan 2014
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Oct 31, 2016
Last update
Oct 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01836458
Responsible party
Sponsor
First posted
Apr 19, 2013
Start date
Jan 2014
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Oct 31, 2016
Last update
Oct 31, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NITD 609

Start the discussion